Organization
Candel Therapeutics, Inc., Needham, MA
1 abstract
Abstract
Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.Org: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, NYU Langone Medical Center, New York, NY, Division of Hematology, Oncology, and Palliative Care, Massey Comprehensive Cancer Center, Virginia Commonwealth University Health System, Richmond, VA, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, Division of Thoracic Surgery, Division of Pulmonary and Critical Medicine, Mayo Clinic, Rochester, MN,